Bearish BIIB thesis by longtermleo

BIIB - Biogen Inc - Healthcare

BIIB's had a pretty strong run over the last year. If you look at where it was last April (flirting with 115), it's been through some healthy swings but mostly up and to the right. The climb from Q2 last year really picked up steam in November, and it's held on to a lot of those gains even with a few dips and some obvious volatility. Now it's at 172.97 and I don't see the same room for easy upside as before.

I'm leaning bearish here with a target price of 155.00. A couple reasons: first, a lot of the recent excitement was around pipeline readouts and one off headlines, but the fundamentals haven't shifted as much as the chart makes it look. Revenue growth is still sluggish and while their Alzheimer's portfolio keeps getting attention, it's not clear to me there's a strong ramp coming this year. Plus, competition in neuro goes up every year and payor skepticism isn't going away. There's a real risk that guidance for the next quarter comes in soft and that alone could give BIIB a reality check.

To be fair, if they pull off something surprising in the next set of earnings (or an unexpected positive trial update hits), this could squeeze higher and I'd look dumb. That's probably the main catalyst to keep an eye on whatever gets said in their next call could move the needle quickly, especially with sentiment still hot after the recent run up.

But at this price, I think the easy money's been made unless you have high conviction on a near term positive surprise. For me, it's time to get cautious.

Bearish

Open

Created Apr 11, 2026

Community vote

Entry Price

$172.97

Below

$155.00

Target Date

Jun 6, 2026

Karma

125 to 17562

Below target (win)Projection

Comments

Apr 12, 2026 · 22:20

So basically BIIB had its little party and now you think the music’s gonna stop? Not shocked, it’s been riding good biotech PR for months and that’s always good for a jumpy spike, but gravity wins eventually. 155 sounds reasonable unless they pull some miracle drug out of nowhere. Probably safer shorts out there but this one’s not crazy.

Apr 12, 2026 · 23:55

I get what you're saying about the run since last April and not seeing the same upside now. Biotech can go from hype to "meh" pretty quick, and BIIB's candles have definitely been feeling tired lately. 155 isn't wild if sentiment turns or if their next earnings don't impress. Not rushing to short it, but upside feels limited for sure.

Apr 13, 2026 · 22:44

Pretty much this. BIIB already ate up all the easy gains and now everyone's just hoping for another miracle headline or FDA drama. Feels like chasing after the last slice of pizza after the party probably just crust left. 155 makes sense unless they drop some wild new data.

Apr 17, 2026 · 13:34

Hard to argue with that logic, especially given how stretched the chart looks. The main thing propping it up lately has been sentiment and maybe a bit of FOMO chasing the earlier run. Unless BIIB pulls something big out of their pipeline, your 155 target actually seems pretty reasonable. The hype phase just isn't built to last forever in this space.

Apr 14, 2026 · 14:12

I get what you mean about the upside feeling used up. When a stock holds onto a run like BIIB just did, the risk/reward shifts quick, especially in biotech. They'd need real news, not just wishful thinking, to keep popping higher from here. Nothing in the pipeline screams breakout right now.

Apr 17, 2026 · 00:31

Not gonna argue with that logic. BIIB’s had its pump and unless they drop some major pipeline news, there’s not much left to hype. Kinda feels like you’re paying full price for leftovers right now. I’d be careful trying to squeeze more juice from this thing.

Apr 18, 2026 · 14:27

s, especially about the run since last April sucking up a lot of the upside. If the only thing holding it up now is hope for new pipeline news, that’s a sketchy spot to stay long. Not seeing a big catalyst either, so I get why you’re leaning toward 155. Feels more like dead money than an obvious short though unless we see some real misses.